Akebia Therapeutics, Inc.
AKBADrugs in Pipeline
8
Phase 3 Programs
4
Upcoming Catalysts
2
Next Catalyst
This month
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
Erythropoiesis-Stimulating Agent (ESA) Phase 3 Est. Readout
Primary completion for Erythropoiesis-Stimulating Agent (ESA) trial (NCT06901505) in Anemia of Chronic Kidney Disease
Source1 more catalyst beyond 14 days
Start a 7-day free trial to see all upcoming catalysts
Erythropoiesis-Stimulating Agent (ESA)
Anemia of Chronic Kidney Disease
Vadadustat
Anemia
Mircera®
Anemia Associated With Chronic Kidney Disease (CKD)
Darbepoetin alfa
Anemia
IW-1973
Heart Failure With Preserved Ejection Fraction
Epoetin Alfa
Anemia
AKB-6548
Anemia
Praliciguat
Focal Segmental Glomerulosclerosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Erythropoiesis-Stimulating Agent (ESA) | Phase 3 | Anemia of Chronic Kidney Disease | - | - |
Vadadustat | Phase 3 | Anemia | - | - |
Mircera® | Phase 3 | Anemia Associated With Chronic Kidney Disease (CKD) | - | - |
Darbepoetin alfa | Phase 3 | Anemia | - | - |
IW-1973 | Phase 2 | Heart Failure With Preserved Ejection Fraction | - | - |
Epoetin Alfa | Phase 2 | Anemia | - | - |
AKB-6548 | Phase 2 | Anemia | - | - |
Praliciguat | Phase 2 | Focal Segmental Glomerulosclerosis | - | - |